Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1371333 | Bioorganic & Medicinal Chemistry Letters | 2015 | 9 Pages |
Starting from our previously identified novel c-Met kinase inhibitors bearing 1H-imidazo[4,5-h][1,6]naphthyridin-2(3H)-one scaffold, a global structural exploration was conducted to furnish an optimal binding motif for further development, directed by the enzyme inhibitory mechanism. First round SAR study picked two imidazonaphthyridinone frameworks with 1,8- and 3,5-disubstitution pattern as class I and class II c-Met kinase inhibitors, respectively. Further structural optimization on type II inhibitors by truncation of the imidazonaphthyridinone core and incorporation of an N-phenyl cyclopropane-1,1-dicarboxamide pharmacophore led to the discovery of novel imidazopyridine-based c-Met kinase inhibitors, displaying nanomolar enzyme inhibitory activity and improved Met kinase selectivity. More significantly, the new chemotype c-Met kinase inhibitors effectively inhibited Met phosphorylation and its downstream signaling as well as the proliferation of Met-dependent EBC-1 human lung cancer cells at submicromolar concentrations.
Graphical abstractA new class of imidazopyridine-based c-Met kinase inhibitors exhibited nanomolar inhibition against the enzyme and the growth of Met-driven EBC-1 human lung cancer cells.Figure optionsDownload full-size imageDownload as PowerPoint slide